24211-30-1
24211-30-1 結(jié)構(gòu)式
基本信息
6,8-DIMETHYL-4',5,7-TRIHYDROXYFLAVANONE
6,8-DIMETHYL-5,7,4'-TRIHYDROXYFLAVANONE
CYRTOPTERINETIN
CYRTPOTERINETIN
FARREROL
(S)-2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-dimethyl-4-benzopyrone
5,7,4'-Trihydroxy-6,8-Dimethoxyflavanone
(2S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-dimethyl-4H-1-benzopyran-4-one
(2S)-6,8-Dimethyl-4',5,7-trihydroxyflavanone
物理化學(xué)性質(zhì)
常見問題列表
Farrerol observably reduces the production of inflammatory mediators including IL-1β, IL-6, TNF-α, COX-2, and iNOS in LPS-induced RAW264.7 cells via suppressing AKT, ERK1/2, JNK1/2, and NF-κB p65 phosphorylation.
Farrerol attenuates β-amyloid-induced oxidative stress and inflammation through Nrf2/Keap1 pathway in a microglia cell line.
Farrerol inhibits angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway.
Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition.
Farrerol ameliorates acetaminophen-induced hepatotoxicity via activation of Nrf2 and autophagy.
Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinson's disease by suppressing the activation of the AKT and NF-κB signaling pathways.